» Articles » PMID: 38969910

Extracellular Matrix Structure and Interaction with Immune Cells in Adult Astrocytic Tumors

Overview
Publisher Springer
Date 2024 Jul 5
PMID 38969910
Authors
Affiliations
Soon will be listed here.
Abstract

The extracellular matrix (ECM) is a dynamic set of molecules produced by the cellular component of normal and pathological tissues of the embryo and adult. ECM acts as critical regulator in various biological processes such as differentiation, cell proliferation, angiogenesis, and immune control. The most frequent primary brain tumors are gliomas and by far the majority are adult astrocytic tumors (AATs). The prognosis for patients with these neoplasms is poor and the treatments modestly improves survival. In the literature, there is a fair number of studies concerning the composition of the ECM in AATs, while the number of studies relating the composition of the ECM with the immune regulation is smaller. Circulating ECM proteins have emerged as a promising biomarker that reflect the general immune landscape of tumor microenvironment and may represent a useful tool in assessing disease activity. Given the importance it can have for therapeutic and prognostic purposes, the aim of our study is to summarize the biological properties of ECM components and their effects on the tumor microenvironment and to provide an overview of the interactions between major ECM proteins and immune cells in AATs. As the field of immunotherapy in glioma is quickly expanding, we retain that current data together with future studies on ECM organization and functions in glioma will provide important insights into the tuning of immunotherapeutic approaches.

Citing Articles

Cancer-associated fibroblasts in hepatocellular carcinoma: heterogeneity, mechanisms and therapeutic targets.

Li Y, Hamad M, Elkord E Hepatol Int. 2025; .

PMID: 39979756 DOI: 10.1007/s12072-025-10788-5.


Decoding the Role of Kinesin Superfamily Proteins in Glioma Progression.

Saadh M, Ghnim Z, Mahdi M, Chandra M, Ballal S, Bareja L J Mol Neurosci. 2025; 75(1):10.

PMID: 39847238 DOI: 10.1007/s12031-025-02308-9.

References
1.
Abedsaeidi M, Hojjati F, Tavassoli A, Sahebkar A . Biology of Tenascin C and its Role in Physiology and Pathology. Curr Med Chem. 2023; 31(19):2706-2731. DOI: 10.2174/0929867330666230404124229. View

2.
Wang M, Wang T, Liu S, Yoshida D, Teramoto A . The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol. 2004; 20(2):65-72. DOI: 10.1007/BF02483449. View

3.
Zhou W, Fong M, Min Y, Somlo G, Liu L, Palomares M . Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014; 25(4):501-15. PMC: 4016197. DOI: 10.1016/j.ccr.2014.03.007. View

4.
Mirzaei R, Sarkar S, Dzikowski L, Rawji K, Khan L, Faissner A . Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Oncoimmunology. 2018; 7(10):e1478647. PMC: 6169571. DOI: 10.1080/2162402X.2018.1478647. View

5.
Shi Y, Ping Y, Zhang X, Bian X . Hostile takeover: glioma stem cells recruit TAMs to support tumor progression. Cell Stem Cell. 2015; 16(3):219-20. DOI: 10.1016/j.stem.2015.02.008. View